Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-05-19 |
地点
California, United States
中国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT05382741 |
Title无病变证据 (NED) 的 IV 期结直肠癌患者的 Durvalumab 加瑞戈非尼辅助治疗与未治疗对照组对比：VIVA 试验 | 阶段
第二阶段
|
Date Added 2022-05-19 |
地点
意大利
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga |
标签
MSS/ MMRp
|
| NCT ID NCT05350917 |
TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | 阶段
第二阶段
|
Date Added 2022-04-28 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05349890 |
TitlePersonalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | 阶段
第 1 阶段
|
Date Added 2022-04-27 |
地点
Oregon, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
CDX-1140, Pembrolizumab, Keytruda |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-04-19 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Disitamab vedotin, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05328908 |
Title一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究 | 阶段
第三阶段
|
Date Added 2022-04-14 |
地点
Arkansas, United States
California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Indiana, United States Massachusetts, United States Michigan, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States 阿根廷 澳大利亚 Austria 比利时 加拿大 智利 中国 Czechia 法国 德国 意大利 日本 大韩民国 荷兰 波兰 波多黎各 新加坡 西班牙 瑞典 瑞士 台湾 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga |
标签
MSS/ MMRp
|
| NCT ID NCT05319314 |
TitleGCC19CART for Patients With Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2022-04-08 |
地点
California, United States
Colorado, United States Massachusetts, United States Michigan, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
GCC19CART |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05308446 |
TitleTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | 阶段
第二阶段
|
Date Added 2022-04-04 |
地点
Arizona, United States
California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States 波多黎各 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT05299840 |
Title使用 Oncogramme(R) 设备为转移性结直肠癌患者选择一线治疗方案的影响 | 阶段
不适用
|
Date Added 2022-03-29 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05292417 |
TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC | 阶段
第二阶段
|
Date Added 2022-03-23 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, GM-CSF, Sintilimab |
标签
MSS/ MMRp
|
